FDA Oversight Of Rx Compounding Should Increase, GAO Study Suggests
Executive Summary
Increased FDA oversight of pharmacy compounding may be necessary due to state budgetary constraints, an Oct. 23 General Accounting Office report suggests
You may also be interested in...
FDA Warns Compounding Pharmacies On Ribavirin, Propulsid Versions
A recent spate of enforcement actions by FDA against compounding pharmacies includes citations for compounded versions of ribavirin and Propulsid
FDA Warns Compounding Pharmacies On Ribavirin, Propulsid Versions
A recent spate of enforcement actions by FDA against compounding pharmacies includes citations for compounded versions of ribavirin and Propulsid
FDA Advisory Committee Line-Up Shrinks With Elimination Of Two Panels
FDA will reduce its total advisory committee count to 30 with the termination of the Pharmacy Compounding and Medical Imaging Drugs Advisory Committees